10-Q: Zeo ScientifiX Reports Q1 2025 Results: Revenue Declines Slightly Amid Strategic Shifts

Zeo ScientifiX's Q1 2025 revenue decreased slightly due to lower biologic product sales, offset by growth in its PPX service platform.

Summary

• Zeo ScientifiX, Inc. reported its financial results for the quarter ended January 31, 2025.
• Revenue decreased by 5.5% to $1,090,000, compared to $1,154,000 in the same period last year.
• The decrease in revenue was primarily due to a 22.2% decrease in biologic product sales.
• This was partially offset by a 1.0% increase in average sales prices for high concentration biologic products and a 285.8% increase in revenue from the PPX service platform.
• Cost of revenues increased by 19.9% to $191,000, compared to $159,000 in the prior year.
• Gross profit decreased to $899,000 (82.5% of revenues) from $995,000 (86.2% of revenues).
• General and administrative expenses decreased slightly by 0.2% to $2,152,000.
• The net loss was $1,243,000, or $0.20 per share, compared to a net loss of $1,040,000, or $0.17 per share, in the prior year.
• The company's cash position at the end of the quarter was $720,000, compared to $657,000 at the beginning of the period.
• The company has a working capital deficit of $2,259,000 and a stockholders deficit of $1,805,000 as of January 31, 2025.
• The company's independent auditors report included an explanatory paragraph as to the company's ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with declining revenue, increasing losses, and going concern doubts. While there are some positive aspects like PPX revenue growth, the overall sentiment is negative due to the company's financial instability and regulatory risks.

Positives

• Revenue from the PPX service platform increased significantly by 285.8%.
• General and administrative expenses decreased slightly by 0.2%.
• Cash position increased from $657,000 to $720,000 during the quarter.
• The company is actively exploring further development of additional products to be used in other topical aesthetic applications.

Negatives

• Overall revenue decreased by 5.5%.
• Biologic product sales decreased by 22.2%.
• Gross profit decreased.
• Net loss increased.
• The company has a significant working capital deficit of $2,259,000.
• The company has a significant stockholders deficit of $1,805,000.
• Auditors have raised concerns about the company's ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is in doubt.
• The company is subject to FDA regulations regarding the sale of biologics.
• The company's products may be subject to the FDA's enforcement policies regarding HCT/Ps.
• The company may not be able to obtain the required licenses from the FDA.
• The company's current market capitalization, common stock liquidity and available authorized shares may hinder its ability to raise equity proceeds.
• The company is involved in a legal proceeding regarding a breach of contract claim.
• The company relies on its ability to produce and sell products it manufactures that are subject to changing technology and regulations that it currently sells and distributes to its customers.

Future Outlook

The company is pursuing efforts to complete its already approved clinical studies as well as obtaining approval to commence additional studies for other specific indications it has identified that the use of its products will provide more favorable and desired health related benefits for patients seeking alternative treatment options than are currently available. The ability of the Company to succeed in these efforts is subject to among other things, the Company having sufficient available working capital to fund the substantial costs of completing clinical trials, which the Company currently does not have, and ultimately, obtaining approval from the FDA.

Management Comments

• Management anticipates that the Company will remain dependent, for the near future, on additional investment capital to fund ongoing operating expenses and research and development costs related to development of new products and to perform required clinical studies in connection with the sale of its products.
• Management cautions all readers that the forward-looking statements contained in this Report are not guarantees of future performance, and management cannot assure any reader that such statements will be realized or the forward-looking events and circumstances will in fact occur.

Industry Context

The company operates in the biopharmaceutical and regenerative medicine industries, which are subject to significant regulatory oversight by the FDA. The company faces competition from other companies in these industries, and its success depends on its ability to develop and commercialize innovative products.

Comparison to Industry Standards

• It is difficult to compare Zeo ScientifiX's results directly to industry standards due to its unique product offerings and stage of development.
• Many comparable companies are either privately held or have different business models.
• However, the company's revenue decline and increasing net loss are concerning and suggest that it is underperforming compared to some of its peers.
• The company's working capital deficit and auditor's concerns about its ability to continue as a going concern are also significant red flags.
• Companies like Organogenesis and Vericel, which are focused on regenerative medicine, have shown more stable revenue growth and stronger financial positions.
• Zeo ScientifiX needs to demonstrate significant improvement in its financial performance to be competitive in the long term.

Management Changes

Legal Proceedings

• Howard Golub, M.D., filed a complaint against the Company alleging a breach of contract as a result of the Company's failure to pay Plaintiff severance in the amount of $150,000 in connection with the non-renewal of the Plaintiff's employment agreement with the Company.

Related Party Transactions

• For the three months ended January 31, 2025 and 2024, the Company sold a total of approximately $ 0 and $ 35,000 of product to a management services organization (MSO) that provides administrative services and contracts for medical supplies for several medical practices, of which Dr. George Shapiro, the Company's Chief Medical Officer and a member of the board of directors has an indirect economic interest in the parent company that owns the MSO.
• During November 2024, the Company received a capital call notice from Exotropin, in which the Company's pro-rata share was $126,000.

Stakeholder Impact

• Shareholders face the risk of further dilution if the company raises additional capital.
• Employees face uncertainty due to the company's financial instability and potential restructuring.
• Customers may be concerned about the company's ability to continue supplying its products and services.
• Creditors face the risk of non-payment if the company's financial situation does not improve.

Next Steps

• The company intends to relocate its operations to the BioXtek Facility by May 31, 2025.
• The company and BioXtek will establish a jointly-owned special purpose entity (SPE) to pursue the development and commercialization of agreed upon products.
• The company and BioXtek have agreed to work in good faith towards the preparation, authorization, execution and delivery of a series of definitive agreements documenting the Joint Venture.
• The company will amortize $ 104,000 of stock-based compensation expense over the remaining term of the agreement with the independent sales representative beginning when the Representative has met the vesting conditions.

Key Dates